(2) The BRAFV600E mutation promotes methylation of the thyrotropin receptor (TSHR) gene promoter, leading to TSHR silencing or a significant decrease in expression, increasing the feedback of thyrotropin (TSH), and promoting tumor cell growth [25]. The gene discussed is TSHR; the disease is neoplasm.